Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia |
| |
Authors: | Minako Yamaoka-Tojo Taiki Tojo Rie Kosugi Yuko Hatakeyama Yuki Yoshida Yoji Machida Naoyoshi Aoyama Takashi Masuda Tohru Izumi |
| |
Affiliation: | (1) Department of Rehabilitation, Kitasato University School of Allied Health Sciences, 1-15-1 Kitasato, 228-8555 Sagamihara, Kanagawa, Japan;(2) Department of Cardioangiology, Kitasato University School of Medicine, 1-15-1 Kitasato, 228-8555 Sagamihara, Kanagawa, Japan |
| |
Abstract: | Background Ezetimibe (Zetia?) is a potent inhibitor of cholesterol absorption that has been approved for the treatment of hypercholesterolemia. Statin, an inhibitor of cholesterol synthesis, is the first-choice drug to reduce low-density lipoprotein-cholesterol (LDL-C) for patients with hypercholesterolemia, due to its strong effect to lower the circulating LDL-C levels. Because a high dose of statins cause concern about rhabdomyolysis, it is sometimes difficult to achieve the guideline-recommended levels of LDL-C in high-risk patients with hypercholesterolemia treated with statin monotherapy. Ezetimibe has been reported to reduce LDL-C safely with both monotherapy and combination therapy with statins. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|